UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results
BRUSSELS and ATLANTA, Feb. 4, 2022 /PRNewswire/ — UCB, a global biopharmaceutical company, today announced positive topline results from the RAISE (NCT04115293) triali evaluating its investigational treatment zilucoplan, a self-administered, subcutaneous (SC) peptide inhibitor of…
Comments Off on UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results